LivaNova Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Vladimir Makatsaria

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2yrs
Yönetim Kurulu ortalama görev süresi	3.2yrs

Son yönetim güncellemeleri

Recent updates

CEO

Vladimir Makatsaria (51 yo)

less than a year

Görev süresi

Mr. Vladimir A. Makatsaria has been the Chief Executive Officer and Director at LivaNova PLC since March 01, 2024. He is a Non-Executive Director of the Health Products Regulatory Authority Board in Irelan...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Alex Shvartsburg	Chief Financial Officer	4yrs	US$2.77m	0.034% R$ 5.5m
Michael Hutchinson	Senior VP	2yrs	US$2.07m	0.0042% R$ 676.8k
Vladimir Makatsaria	CEO & Director	less than a year	Veri yok	Veri yok
Lindsey Little	Senior Director of Investor Relations	no data	Veri yok	Veri yok
Deanna Wilke	Vice President of Corporate Communications	no data	Veri yok	Veri yok
Matthew Dodds	Senior Vice President of Corporate Development & IT	6.8yrs	Veri yok	Veri yok
Paul Buckman	President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement	no data	Veri yok	Veri yok
Stephanie Bolton	President of Global Epilepsy	4.8yrs	Veri yok	0.018% R$ 2.8m
Ahmet Tezel	Chief Innovation Officer	less than a year	Veri yok	Veri yok
Franco Poletti	President of Cardiopulmonary Business Unit	less than a year	Veri yok	0.013% R$ 2.0m
John Webb	Vice President of Sleep Apnea and Epilepsy	no data	Veri yok	Veri yok
Jonathan Walker	VP for Difficult-to-Treat Depression Segment	no data	Veri yok	Veri yok

2.0yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: L2IV34 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Vladimir Makatsaria	CEO & Director	less than a year	Veri yok	Veri yok
Todd Schermerhorn	Independent Non-Executive Director	3.9yrs	US$270.00k	0.011% R$ 1.8m
Peter Wilver	Independent Director	2.4yrs	US$263.00k	0.0069% R$ 1.1m
William Kozy	Chairman of Board	6.4yrs	US$3.34m	0.051% R$ 8.1m
Sharon O'Kane	Independent Non-Executive Director	9.1yrs	US$281.43k	0.017% R$ 2.8m
Stacy Seng	Independent Non-Executive Director	5.4yrs	US$260.00k	0.016% R$ 2.6m
Francesco Bianchi	Independent Non-Executive Director	9.1yrs	US$263.00k	0.016% R$ 2.6m
Susan Podlogar	Independent Director	less than a year	Veri yok	Veri yok
J. Barry	Independent Director	1.1yrs	US$117.88k	Veri yok
Brooke Story	Independent Director	2.2yrs	US$248.00k	0.0064% R$ 1.0m

3.2yrs

Ortalama Görev Süresi

60.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: L2IV34 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.2 yıldır).

LivaNova Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

LivaNova PLC Appoints Susan Podlogar as New Director

Trui Hebbelinck Leaves Position of LivaNova Plc's Chief Human Resources Officer

Daniel Jeffrey Moore Resigns as Director of LivaNova PLC

LivaNova PLC Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

LivaNova PLC, Annual General Meeting, Jun 11, 2024

LivaNova PLC Announces CEO Changes, Effective on March 1, 2024

Recent updates

LivaNova PLC Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

LivaNova PLC Appoints Susan Podlogar as New Director

LivaNova PLC to Report Q3, 2024 Results on Oct 30, 2024

Trui Hebbelinck Leaves Position of LivaNova Plc's Chief Human Resources Officer

LivaNova PLC Provides Earnings Guidance for the Year 2024

LivaNova PLC to Report Q2, 2024 Results on Jul 31, 2024

Daniel Jeffrey Moore Resigns as Director of LivaNova PLC

LivaNova PLC Provides Update on Recover Clinical Study Evaluating Vns Therapy for Treatment-Resistant Depression in Unipolar Patients

LivaNova PLC Provides Earnings Guidance for the Full-Year 2024

LivaNova PLC Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

LivaNova PLC, Annual General Meeting, Jun 11, 2024

LivaNova PLC to Report Q1, 2024 Results on May 01, 2024

LivaNova PLC Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea

Livanova plc Announces Impairment Charges for the Three Month Ended December 31, 2023

LivaNova PLC Announces CEO Changes, Effective on March 1, 2024

LivaNova PLC to Report Q4, 2023 Results on Feb 21, 2024

Livanova plc Provides Revenue Guidance for the Full-Year 2023

LivaNova PLC Announces Board Changes

Marco Dolci to Retire as President of Cardiopulmonary Business Unit of LivaNova PLC on December 31, 2023

LivaNova PLC to Report Q3, 2023 Results on Nov 01, 2023

LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark

LivaNova PLC Provides Financial Guidance for the Full Year 2023

LivaNova PLC to Report Q2, 2023 Results on Jul 26, 2023

LivaNova PLC Announces 150th Bipolar Depression Patient Randomized in Recover Clinical Study

LivaNova PLC Provides Earnings Guidance for the Full Year 2023

LivaNova PLC Initiates Limited Commercial Release in Europe of the Essenz Perfusion System for Cardiopulmonary Bypass Procedures

LivaNova Launches SenTiva DUO

LivaNova PLC to Report Q4, 2022 Results on Feb 22, 2023

LivaNova PLC Announces Management Changes

LivaNova PLC to Report Q3, 2022 Results on Nov 02, 2022

LivaNova PLC Appoints Brooke Story as New Director

LivaNova PLC Provides Earnings Guidance for the Full Year 2022

LivaNova PLC to Report Q2, 2022 Results on Aug 03, 2022

LivaNova PLC Announces Executive Changes

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş